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Recent study of 400 human cases, including 240 with diverse hemorrhagic
disorders, has accumulated noteworthy experience with a wide variety of
test methods for quantitating the collective and individual factors in the
blood clotting and hemostatic mechanisms. Important among these tests are
those dealing with prothrombin and its conversion to thrombin for the
enzymatic polymerization of fibrinogen to fibrin clot. The so-called "pro-
thrombin time" test, originated by Quick et al.,2" has been compared in this
investigation with three specific prothrombin methods. Ware and Seegers2'
made detailed studies of the technical aspects of the "2-stage" prothrombin
assay method originated by Warner ,Brinkhous, and Smith.' The present
communication deals with our experience bearing on the validity of this
method and its modifications, including some of our own, based uponl
experiments of a technical nature, with the opportunities for using test
plasmas and sera from a representative collection of cases with bleeding
disorders.
MATERIALS AND METHODS
Blood is obtained from an arm vein using a siliconed syringe. Some is clotted in
glass at 370 C. and after 1 hour is mixed with 1/10 vol. of 0.1 M sod. oxalate and
centrifuged for the serum, which is used in the prothronmbin consumnption test. This
test gives the percentage loss of prothrombin after 1 hour at 37' C. as computed from
assays on serum and the corresponding plasma (see below). Another blood sample is
oxalated immediately and centrifuged for plasma, which is used for many tests. "One-
stage" methods'8 following a basically similar procedure are: (a) prothromlbin time
(PT) test, (b) specific prothrombin assay (Method I), (c) specific proconvertin
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assay, (d) specific proaccelerint assay. The common procedure is to time the clotting
at 370 C. after adding 0.2 ml. Ca-tpln. to the various plasma mixtures. "Ca-tpln." is
equal vols. of 0.02 M CaCI2 and tissue thromboplastin, the preferred preparation being
"soluplastin,"* since our tests show this to be free from (pro)convertin and (pro)-
accelerin contaminants. The respective "substrates" are: (a) for PT test (cf."),
simply 0.1 ml. of patient's plasma (pp) ; (b) for prothrombin assay (cf.'), 0.1 ml.
1: 10 pp (sal. dil.) plus 0.1 ml. proconvertin'3-enriched beef BaSO4-plasma; (c) for
proconvertin assay (cf.'0), 0.1 ml. 1: 10 pp plus "asbestos-filtered" beef plasma; (d)
for proaccelerin assay (cf.'), 0.1 ml. 1: 10 BaSO4-pp plus "aged" human normal
plasma. The principle is that each substrate supplies all the necessary clotting factors
except the one being assayed.
"Nornial" standards, reference (dilution) curves, and reagent checks for these and
other tests involve much meticulous experimentation. They permit assays in terms of
"per cent" of normal, in each case, whether a reference curve is used or a statistical
norm for an empirical (e.g., 2-stage prothrombin) unitage. A known normal is
assayed with each group of tests to orient the standard to any change of reagents or
test conditions.
BaSO4 adsorption, of plasma, serum, or fibrinogen solutions, is effected by mixing
with powdered BaSO4 (Merck's), 0.1 gm. per ml., for 10 minutes at 37° C. and cen-
trifuging off the sediment. This sediment may be eluted with ½3 vol. of 0.2 M sod.
citrate for a new specific 2-stage prothrombin assay (Method III) First, incubate
0.1 ml. eluate with 3.7 ml. saline (0.85% NaCl), 1 ml. imidazole buffer (pH: 7.3),
0.1 ml. accelerin (BaCO3-adsorbed beef serum,' 1: 8 dil.), 0.1 ml. beef proconvertin
(cf."8), 0.5 ml. "soluplastin," 0.5 ml. 0.15 M CaCl2. Secondly, time the clotting, at
280 C., of 0.2 ml. fibrinogen with 0.2 ml. samples of incubate at successive minute
intervals. Clotting-times are referred to a standard normal eluate dilution curve to
assay prothrombin as "percentage" (of normal). Like the orthodox 2-stage (Method
II), the new test activates the prothrombin (but in the fibrinogen-free eluate) to
thrombin, which is then measured by the shortest clotting-time for a standard fibrino-
gen. The end-point is usually reached within 5 minutes and is typically stable (unlike
II), indicating absence of thrombin-inactivating inhibitors. Other differences from the
orthodox two-stage are non-use of acacia, employment of a fixed dilution, and a
different mode of computation.
The orthodox 2-stage (Method II) for specific prothrombin assay: Defibrination of
plasma is effected by collecting fibrin on a glass rod for 15 minutes after adding 0.1 ml.
thrombin to 0.5 ml. plasma plus 0.4 ml. saline. The bovine thrombin of the Upjohn Co.,
supplied through the courtesy of Dr. J. T. Correll, is very satisfactory when used in
a strength of 20 "units" per ml. Dilution of the defibrinated plasma is (IIa) with
saline, in the "original"2" method, (IIb) with 1:150 saline dil. BaCO3-adsorbed beef
serum (AcG or accelerin) in the "modified"' method, and (IIc) with AcG plus 1:100
beef proconvertin (ProC)"8 in our "improved" method. Activation of the suitably
diluted defibrinated plasma is by incubation of 0.6 ml. with 1.8 ml. of (a) Difco's
"prothrombin incubation mixture," supplied through the courtesy of Dr. C. W.
Christensen, or (b) our own preferred "mix" (cf.'), viz. 23 saline, 2 imidazole buffer,
8 acacia (15%, Ca-free), 1.2 "soluplastin," 1.8 CaC12 (0.1 M). At minute intervals,
* Schieffelin and Co., supplied through the courtesy of Dr. E. W. Blanchard.
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0.4 ml. of incubate is tested on 0.1 ml. fibrinogen, at 280 C., until the shortest clotting-
time is reached. Computation and correction factors are established.'3
Fibrinogent. A very satisfactory fibrinogen is prepared from dog plasma, after
BaSO4 adsorption, by precipitation at V4 saturation with (NH4)2SO0, redissolvinig in
saline and dialyzing against saline containing 0.005 M sod. citrate. Armour's bovine
fibrinogen (Fraction I) is serviceable if a 1-1.5% solution is adsorbed with BaSO4
anid then dialyzed to low citrate content. Stock solutions are stored frozen at -20° C.
in 10 ml. lots, and centrifuged free of sediment on first thawing before use.
RESULTS AND INTERI'RETATIONS
Parallel tests on 100 normal and
over 200 hemorrhagic cases show
that the results with Method Ilb or
Ilc agree closely with those by
the other two specific prothrombin
methods I or III, but often diverge
widely from those of the prothrom-
bin time test. If Method II is com-
pared with either Method I or
Method III a linear correlation is
shown, with a small scatter and a
computed correlation coefficient of
over 0.95. Figure 1 in contrast com-
pares data of Method II and the
prothrombin time test. The discrep-
ancies are obvious and the correla-
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FIG. 1. Comparison of two-stage pro-
thrombin assays (Method II) and pro-
thrombin time tests expressed as percen-
tages of normal.
tion coefficient of about 0.5 is hardly significant. Independent assays of
other factors show what is now well recognized, namely, that the original
one-stage "prothrombin" test is subject to other variables. These include
proaccelerin (Ac-globulin, labile factor, factor V, etc.), proconvertin
(SPCA, stable factor, factor VII, etc.), as well as the abnormal presence of
certain inhibitors and, rarely, severe deficiencies of fibrinogen. Another pre-
viously reported finding is that of a normal prothrombin time test in new-
born infants despite considerable deficiency of prothrombin and procon-
vertin." Some 30 cord blood plasmas are included in Figure 1. In all these
cases there was an abnormally high (100-300%,) proaccelerin.
Granting, then, that the three "specific" methods all measure the same
clotting component, what is the evidence that this is indeed prothrombin?
One direct answer was given by Johnson and Ferguson,"2 who used Method
II to show excellent analytical recoveries of purified prothrombin added to
normal human plasma.
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Effects of technical variables, including those dependent on reagents. The
present study confirms an earlier report2" that Method II is very dependent
upon technical variables as far as any "absolute" unitage is concerned.
Clotting-times are affected by temperature, pH, ionic strength and nature
of salts, etc., present, and by such "fibrinoplastic" additives as the acacia."
Even with this useful (if not physiological) addition, clotting-times and
hence unitage vary with each batch of fibrinogen. However, with one good
lot of fibrinogen and the readily reproducible mixtures of the other reagents,
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FIG. 2. Correlation of prothrombin FIG. 3. Two-stage "prothrombin" assay
unitage (Method II) and known plasma units on normal human plasma during
dilution. storage at -2O° C. Diluents varied.
satisfactory agreement is observed in repeated testing of the same plasma.
For instance, in 10 repeat determinations on one normal plasma the mean
unitage of 385, with range 350415, showss a standard deviation ((r) close
to ±5 per cent. Tests on 50 normal persons gave 360 (267-41, r :12%)
with one dog fibrinogen, 30 gave 265 (200-335, if : 11%So) with Man-
other, while 70 additional cases assayed 215 (160-316, cr:18% ) wvith a
bovine fibrinogen. Evidently, normal individuals showv somle variability in
the 2-stage prothrombin assay, ranging ±30-35%e of the mean (100%o) in
our total series. However, the major determinant of the absolute unitage is
the "reactivity" of the standard fibrinogen. The linear correlation (Fig. 2)
between Method II unitage and known plasma dilutions (using BaSO4
plasma as diluent) extends to the practical limits of the test.
Variation in the type of diluent, in step 2 of Method II, was re-studied.
In the above 10 repeat determinations on a single fresh human plasma,
tests made with simple saline diluent (a) gave 353 (330-398, (X: 5.7%)
wvith the mean at 92%o of that noted above with the AcG-modified (b)
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method. Table 1 shows parallel determinations on known plasma dilutions,
using as diluents: (i) AcG+ProC, (ii) AcG, (iii) ProC, (iv) saline only.
The fact that there was only a slight improvement on adding the accelerin
and proconvertin may be attributed to the fact that these agents were
already sufficient in the fresh normal plasma tested. In these and many
other comparative studies the "improved" (IIc) and the "modified" (Ilb)
tests agreed closely, with the former usually giving a few extra units.
TABLE 1. TWO-STAGE PROTHROMBIN ASSAYS ON SALINE DILUTIONS
OF NORMAL HUMAN OXALATED PLASMA
Actual %o Found values, zwith specified diluents* (in test):
strength (1) AcG+ProC. (2) AcG. (3) Sal.+ProC. (4) Sal.
5 4.4 4. 3.9 3.7
10 8.4 7.6 7.6 7.8
20 18. 18. 17. 18.
40 36. 34. 30. 31.
60 57. 54. 55. 54.
80 78. 75. 72. 79.
100 100. 100. 100. 100.
units/ml. 263 271 255 243
* Diluents, in 0.85 per cent NaCl (Sal.):
1: 150 BaCO3--adsorbed bovine serum (AcG)
1: 100 bovine proconvertin (ProC.)
Influence of plasmia proaccelerin. That loss of labile proaccelerin (AcG)
is the cause of unduly low 2-stage prothrombin unitage when testing aged
plasmas was shown by Fahey, Ware, and Seegers.8 Figure 3 confirms this
in the case of a normal human plasma stored frozen at -20° C. in 0.5 ml.
lots which were thawed and tested individually over a period of 50 days.
Even this excellent cold storage did not prevent a drop in unitage by the
"original" Method Ila (square symbols saline diluent, only), although
this levelled off in the second week and the precipitous drop in the sixth
week was associated with a (41st day) thawing (defrosting) and refreez-
ing, which we have frequently found to cause disappearance of proaccelerin.
The "modified" 2-stage (open circles) shows very satisfactory reproduci-
bility of the true prothrombin unitage. The "improved" method (dark
symbols) gives only small increases in unitage, which agrees with the cur-
rently accepted fact that proconvertin, like prothrombin, survives w-ell in
preserved plasma and a normal specimen does not need additional ProC
in the test diluent.
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Data on D. H. (Table 2), a clinical case of congenital hypoproacceleri-
nemnia (proaccelerin assays: 0),'" the disease originally called "parahemo-
philia" by Owren,"' showed a false low prothrombin value of 47 units with
saline diluent, but 310 units (117% of normal) with the AcG-modified
test. Hoxvever, the optimal activation time was reduced only from 5 to 3
minutes. Proconvertin addition did not significantly change these figures.
D. H.'s plasma proconvertin assayed 98% (of normal).
Acquired hypoproaccelerinienmias have occurred in a number of our clini-
cal cases, with associations that include liver diseases, tromexan therapy,
etc. They also require the "modified" or "improved" 2-stage for assay of
true prothrombin unitage.
Influence of plasmta proconvertin. The stability of proconvertin, as shown
in Figure 3 (interpreted above), precludes attempts to ascertain its r6le in
the 2-stage assay except on plasmas with markedly lowered proconvertin
levels. Such are available in cases of congenital hypoproconvertinemtia
originally described as SPCA-deficiency by Alexander et al.' in 1950. In
that year we9 reported two cases (M. T. and R. D., correction: R. S.) as
congenital hypoprothrombinemics unresponsive to vitamin K1 oxide. Our
reappraisal in 195318 was based on the following additional tests: M. T., a
14-year-old white girl died in 1950, but we kept some of her frozen plasma
and three years later were able to prove its normal prothrombin (but
absence of proconvertin). This required our specific tests, however. Thus,
the usual AcG-"modified" 2-stage gave prothrombin as 34% (of normal),
whereas our "improved" (ProC+AcG) method raised this to 857%, accept-
ably "normal" on a three-year-old plasma specimen. Moreover, the new test
required a normal 4 minutes, instead of the other's 10 minutes for optimal
activation. R. S., a 32-year-old white male, returned for another study in
1953 and also gave specific proconvertin assay of zero and the following
variants of the 2-stage prothrombin assay, made on a 3-day-old plasma
specimen (kept at -20° C.) : (i) with saline diluent, 33%, after 37 min-
utes ( !) activation; (ii) with AcG, 87%, after 10 minutes activation;
(iii) with ProC (and saline), 79%o, after 16 minutes activation; (iv) with
ProC plus AcG, 103% in a normal 3 minutes activation.
Clearly these two cases (included in Table 2) are congenital hypopro-
convertinemtics, with essentially normal levels of prothrombin. Both gave
very long "prothrombin time" tests (2%c of normal) and could not have
been diagnosed without the use of proconvertin.
The acquired hypoproconvertinemtia cases in our series are almost invari-
ably accompanied by hypoprothrombinemia and some associations are (a)
normal infancy (newborn cord bloods),'1 (b) liver disease, (c) vitamin K
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TABLE 2. TWO-STAGE PROTHROMBIN ASSAYS OF PLASMA (expressed as percentage
of normal) AND PROTHROMBIN CONSUMPTION (percentage loss in serum after
1 hour at 370 C.) IN REPRESENTATIVE CASES OF HEMORRHAGIC DISORDERS.
Method Ilb ("modified") IIc ("improved"), in cases marked
with asterisk
7Type of disorder
Normal (control)
Congenital hypoproaccelerinemia
Congenital hypoproconvertinemia
Low proconvertin; high proaccelerin:
Low PTC
Hemophilia (AHG lack): mild
99 : mild
"t : severe
PTC-deficiency (no inhibitor)
Plasnma
prothr.
100
117
Prothrombin
consumption
98 (>90)
40
85* 79*
103* (70) 60* (67)
43 (mean) 83 (mean)
(30-59) (55-95)
117 33
82 62
107 0
85 19
100 0
PTA-deficiency 76
Hemophilia + inhibitor (anti AHF) 75
PTC deficiency + inhibitor (anti PTC) 83
"idiopathic" circulating anticoagulant 70
Platelet and Vascutlar Disorders (platelets x 103)::
Acquired thrombocytopenia (10)
Familial thrombocytopenia (38)
" post-splenectomy (320)
Thrombopathic purpura (238)
Thrombopathic purpura (230)
Thrombocytosis (>2,000)
Sch6nlein-Henoch's purpura (322)
"Pseudohemophilia" (376)
Hereditary telangie^tasia (298)
Scurvy (452)
Congenital afibrinogenemia
Severe liver disease; hypofibrinogenemia,
hypoproaccelerinemia, active fibrinolysin
lowe'
0
0
0
47
70
95
95
95
97
95
95
97
95
98
114
111
106
90
89
88
77
100
95
122
120
95 0
t Cord bloods.
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Case
J. F.
D. H.
M. T.
R. S.
32 new-
bornt
G. M.
J. K.
W. B.
R. J. (1)
Q. C.
W. C.
R. J. (2)
L. T.
V. Y.
A. B. (1)
A. B. (2)
S. C.
N. P.
R. G.
J. W.
D. Q.
Z. M.
W. M.
D. B.
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deficiency (infants), (d) cases on dicumarol or tromexan therapy. The
course of these cases can be followed either with the specific methods or
with the prothrombin time test. In all of them the hypoproconvertinemia is
moderate and our "improved" Method II prothrombin assay does not show
significant differences from the ordinary "modified" 2-stage. Figure 4
shows the results of these two variants of the prothrombin assay, (a) open
circles: AcG-saline; (b) open squares: ProC-+AcG diluent, and compares
them with (c) the "prothrombin time" determinations: solid circles, in a
CASE OF MYOCARDIAL INFARCTION
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FIG. 4. Prothrombin time tests (dark circles), "modified" (open circles) and
"improved" (open squares) two-stage prothrombin assays during course of tromexan
therapy in a case of myocardial infarction.
case under tromexan therapy. The much lower values in (c) (cf.") indicate
this test's sensitivity to lowering of proconvertin as well as of prothrombin.
We have not encountered any case of genuine congenital hypoprothroml-
binemtia, and the existence of such a state has even been questioned.'
The "improved" and "modified" 2-stage prothrombin methods have been
found equally reliable on all other types of bleeding disorders. The latter
method wvas used in the selected cases of Table 2, but in the two cases of
hypoproconvertinemia (see above), corrected values (marked with aster-
isks) were by the "improved" method. This table also illustrates another
use of the 2-stage method, namely, in estimating prothrombin consumption,
although for this test the simplicity of our 1-stage (Method I) is to be
preferred. High serum prothrombin values, indicating defective prothrom-
bin consumption, are noted in hemophilia (AHF deficiency)' or hemophilia-
like disorders, viz., PTC-deficiency,"" PTA-deficiency,23 and "4th. (D)
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factor"24 lack. Table 2 shows the normal plasma-but abnormal serum-
prothrombin levels in typical cases of three of these diseases. A hemophiliac
(W.C.) and a PTC-deficient patient (for several months, R. J.) showed
circulating inhibitors following transfusion therapy,"7 but these did not sig-
nificantly interfere with the prothrombin determinations. Another ("idio-
pathic") case (L.T.) with circulating anticoagulant gave a somewhat low
plasma prothrombin assay. Their prothrombin time tests were fairly normal,
however.
Heparin is a natural (but probably pathological) anticoagulant, which
the originators' of the 2-stage prothrombin method considered to interfere
TABLE 3. INFLUENCE OF THROMBIN STRENGTH* AND OF HEPARINt ON
UNITAGE OBTAINED IN TWO-STAGE PROTHROMBIN ASSAY:
HUMAN PLASMA
Sal. Hep.t Hep.f Sal. Hep.t Sal.
Thrombin strength* 10 10 3 2 2 0.5
Defibrination C. T. (sec.) 7.8" 9.2"f 60" 19.4" tr. 78"
Unitage, per ml. plasma 234 268 321 325 265 291
* Thrombin strength: Units per ml. of plasma mixture.
t Heparin = 0.1 units (0.001 mg.) per ml. of plasma.
with the test. Johnson and Ferguson12 confirmed this experimentally, with
excessive amounts of heparin, but found that smaller amounts (equivalent
to plasma levels in heparin anticoagulant therapy) caused an inexplicable
increase in the 2-stage prothrombin unitage. Table 3 presents some recent
tests which confirm this last point and also offer an explanation. Normal
human plasma was heparinized to 0.1 Toronto unit (1 microgram) per ml.
In parallel tests, with and without heparin, the strength of thrombin used
in the defibrination was also varied. The finding of an anomalous elevation
in the prothrombin unitage occurred in the heparinized samples only when
the thrombin was unduly strong. It never exceeded the unitage with optimal
strength thrombin (without heparin). It is suggested that there is an opti-
mal strength for the thrombin used in the defibrination step of the assay.
WVhen the thrombin is too strong, a little heparin (which, with plasma
cofactor, is inhibitory to thrombin) can correct this.
Radiation sickness. An addition to the literature2 on the subject of
radiation hemorrhage is the human case (R. T.) presented in Table 4. This
elderly male had liver carcinoma metastasizing from a primary site in the
colon and was under treatment with radiogold (Au198) at the Oak Ridge
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Hospital (ORINS) when we made the cited tests, reproduced (with per-
mission) in Table 4. The studies made on the day before the Au198 injec-
tion showed a normal plasma prothrombin but deficient prothrombin con-
sumption. Residual (1 hour) serum percentage is stated. By the 4th day,
prothrombin consumption was back to normal and remained so until the
19th day, becoming increasingly defective until the 22d day; the patient
died next day from a massive hemorrhage at the primary carcinoma site.
Plasma prothrombin levels fluctuated but were abnormally low only termi-
nally. The last two observations of diminished prothrombin consumption
TABLE 4. PROTHROMBIN CONSUMPTION TESTS (TWO-STAGE) ON CASE OF LIVER
CARCINOMA (METASTASIS) TREATED WITH RADIO-GOLD (Au198)
Day of therapy -1 4 8 13 19 22
Plasma pro. (u./ml.) 510 470 313 340 445 184
Serum, 1 hour
Resid. pro. (%) 23 1 2 2 20 45
Platelets x 103 243 280 235 420 158 43
could be correlated with developing thrombocytopenia, but platelet counts
were normal in the earlier tests.
Thrombocytopenias are typically accompanied by normal plasma pro-
thrombin levels, but deficiency of prothrombin consumption.' In Table 2,
Case V. Y., with a platelet count of 10,000 per mm.,3 is typical, and case
A. B. shows recovery after splenectomy.
We have quantitative tests for platelet functions, viz., (a) thromboplastin,
(b) accelerator factor, (c) clot retractor factor, and (d) vasoconstrictor
fiactor (5 hydroxytryptamine). Cases with normal numbers of platelets may
be functionally deficient ("thrombocytopathia"), and in Table 1, S. C.
lacked (a) and (b) and N. P. lacked the retractor factor. However, both
showed normal prothrombin levels and normal prothrombin consumption.
This is the case also when platelets are in excessive numbers, e.g.,
>2,000,000 per mm.,3 in case R. G. (an atypical leukemia). The other
(vascular, etc.) types of purpuras illustrated give normal platelet and
prothrombin tests. Prothrombin tests (with fibrinogen added) are normal
in congenital afibrinogenentia (D. B.)`A Acquired hypofibrinogenentia, e.g.,
in severe liver disease, is usually accompanied by severe hypoprothrombi-
nemia, often hypoproconvertinemia, and other clotting factor anomalies.
Case X. P. was unusual in showing normal plasma prothrombin, but
absence of prothrombin consumption. A complete analysis of this case
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would require tests beyond the scope of the present investigation. The
significant factor may be the active fibrinolysin, destroying proaccelerin as
well as fibrinogen, the prothrombin and plasmatic thromboplastic factors
being resistant.
CONCLUSIONS
Technical study and clinical laboratory use attest the value of the two-
stage assay as a true measure of prothrombin in plasma and in serum. The
test must be "modified" to ensure adequacy of (pro)accelerin and, in severe
deficiencies, of (pro)convertin also. Clinical applications here illustrated
include (i) differential diagnosis of genuine hypoprothrombinemias (even
in "mixed" deficiencies) from cases lacking the "accessory" factors, namely,
proconvertin or proaccelerin; (ii) the following of the course of prothrom-
bin levels in disease and after giving "hypoprothrombinemic" (dicumarol,
tromexan, etc.) drugs and vitamin K; (iii) also, the following of prothrom-
bin levels in infancy; (iv) the establishing of the essential normality of the
plasma prothrombin level in afibrinogenemia (congenital), hypoproacceleri-
nemia ("parahemophilia"), hypoproconvertinemia (SPCA deficiency),
hemophilia, PTC-' and PTA-23, etc.24 deficiencies, thrombocytosis, thrombo-
cytopenia, thrombocytopathias, vascular purpuras, and radiation sickness
(except terminally). Heparin and perhaps certain other pathological in-
hibitors of clotting may present some technical problems in these tests. The
prothrombin time test is affected by some factors other than prothrombin
but is valuable if this does not confuse the issue. The prothrombin consump-
tion test is another application of "specific" prothrombin assay methods.
The list of hemorrhagic disorders accompanied by defects in prothrombin
consumption has a common denominator, namely, some cause of delayed or
incomplete prothrombin activation. Taken with other modern tests of the
blood-clotting mechanisms, the above techniques are of significant practical
value in the elucidation of many bleeding and clotting disorders.
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